The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Is there promise for fixed-duration BTK and BCL2 inhibitor combination therapy in R/R CLL?
Paolo Ghia, MD, of Vita-Salute San Raffaele University, Milan, Italy, discusses the promise for fixed-duration BTK and BCL2 inhibitor combination therapy in chronic lymphocytic leukemia (CLL) in the relapsed/refractory setting. Dr Ghia highlights that this combination therapy provides a potential retreatment option for patients who have progressed after initial treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
